Jacqueline Lonier, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1003042169
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Vertex accounts for 97.0% of it on its own, with 1 other manufacturer making up the rest.
Across 12 payments — averaging $386.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$4K
- Tandem Diabetes Care, Inc.$140
Across 75 payments — averaging $1098.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sequel Med Tech, LLC$81K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$2,45053%
- Travel & lodging$1,98743%
- Food & beverage$2004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 10 | $4,496 |
| Tandem Diabetes Care, Inc. | 2 | $140 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,636 in reported general payments places this provider in the 70th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $173,449 |
| TrulicityDulaglutide | 60 | $81,767 |
| JardianceEmpagliflozin | 53 | $63,695 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $43,062 |
| MounjaroTirzepatide | 33 | $40,406 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $32,578 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $12,638 |
| NovologInsulin Aspart | 29 | $11,278 |
| Novolog FlexpenInsulin Aspart | 41 | $9,199 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,649 |
| HumalogInsulin Lispro | 20 | $6,842 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 31 | $3,779 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 36 | $3,485 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,940 |
| Levemir FlexpenInsulin Detemir | 12 | $2,904 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.